Definition And Epidemiology

Klinefelter syndrome is the most common sex chromosome aneuploidy in males, characterized by the presence of one or more extra X chromosomes.
The classic karyotype is 47,XXY, which accounts for 80 to 90% of cases.
The condition leads to primary hypogonadism, tall stature, gynecomastia, infertility, and variable neurodevelopmental issues.
The incidence is approximately 1 in 500 to 1000 live male births.
The disorder is frequently underdiagnosed, with only 25 to 50% of cases identified during childhood.

Etiology And Genetics

The extra X chromosome arises from nondisjunction during meiosis in either the maternal or paternal gametes.
Maternal nondisjunction occurs in 50 to 60% of cases and involves a meiosis I or II error, which is associated with advanced maternal age.
Paternal nondisjunction accounts for 40 to 50% of cases and commonly involves a post-zygotic mitotic error.
Classic Klinefelter syndrome is typically a de novo occurrence rather than an inherited trait.

Mosaic variants (46,XY/47,XXY) represent 10 to 15% of cases and are generally associated with a milder phenotype and occasional spontaneous fertility.
Higher-degree aneuploidies, such as 48,XXXY or 49,XXXXY, manifest with severe intellectual disability, cryptorchidism, and skeletal malformations.

In males with an extra X chromosome, X-inactivation occurs, leading to the formation of a Barr body.
However, 15 to 20% of X-linked genes escape this inactivation.
The presence of two active copies of these escape genes causes overexpression, which directly contributes to the characteristic tall stature, hypogonadism, and cognitive phenotypes observed in the syndrome.

Life Stage	Clinical Manifestations
Prenatal And Newborn	- Often undetected, but anomaly scans may reveal increased nuchal translucency or cystic hygroma. - Normal male genitalia at birth, sometimes accompanied by subtle hypotonia or a small phallus.
Childhood	- Tall stature with long limbs and eunuchoid proportions, typically crossing above the 75th percentile by 5 to 8 years of age. - Mild learning difficulties, reading disorders, poor motor coordination, and behavioral issues such as shyness, social withdrawal, and ADHD. - Subtle dysmorphism including a long face, clinodactyly, and pes planus.
Adolescence And Adulthood	- Delayed or absent puberty, small firm testes (<4 mL), and gynecomastia affecting 50 to 75% of individuals. - Sparse facial and body hair, high-pitched voice, reduced muscle mass, and fatigue. - Infertility secondary to azoospermia in over 95% of non-mosaic cases.
Associated Comorbidities	- Increased risk of osteoporosis, metabolic syndrome, and a four-fold increased risk of type 2 diabetes. - Autoimmune diseases such as systemic lupus erythematosus and thyroiditis. - Psychiatric vulnerabilities including anxiety, depression, and a 5 to 10-fold increased risk of schizophrenia.

Peripheral blood karyotype: The gold standard for confirmation, requiring the analysis of at least 20 metaphases to properly detect mosaicism.
Fluorescence in situ hybridization (FISH): Utilized for rapid interphase X chromosome analysis.
Hormonal profiling: Post-pubertal evaluation reveals elevated FSH and LH, low-normal testosterone, and low inhibin B and AMH.
Semen analysis: Confirms azoospermia in post-pubertal patients.

Bone age X-ray: Often advanced during childhood.
Bone densitometry (DEXA): Initiated in adolescence to screen for osteoporosis.
Echocardiography and renal ultrasound: Used to rule out associated, albeit rare, structural anomalies.
Neuropsychological testing: Essential for assessing and managing learning disabilities.

Optimal care requires coordination between a pediatric endocrinologist, geneticist, developmental pediatrician, psychologist, urologist, orthopedist, and speech therapist.

Testosterone therapy is initiated at 11 to 12 years of age.
Low-dose intramuscular, oral, or transdermal administration induces puberty, improves bone density, builds muscle mass, stabilizes mood, and develops secondary sexual characteristics.
Continuous lifelong monitoring of testosterone levels, hematocrit, PSA, and bone density is mandatory.

Testicular sperm extraction (TESE) combined with ICSI yields a 40 to 50% success rate in adolescents and adults.
Orchidopexy is indicated if cryptorchidism is present to mitigate the increased risk of germ cell tumors.
Surgical mastectomy is considered for post-pubertal gynecomastia if it remains persistent and distressing.

Early intervention incorporates speech therapy, occupational therapy, and special education programs.
Behavioral therapy is targeted at managing ADHD and anxiety.
Annual screening is conducted for metabolic syndrome, lipid profile abnormalities, thyroid dysfunction, and bone health.

The recurrence risk for classic de novo 47,XXY is exceptionally low (<1%).
Genetic counselling should be non-directive, emphasizing the variable phenotype and excellent quality of life achievable with early intervention.
Life expectancy is near normal with appropriate testosterone replacement and strict comorbidity management.

The condition remains underdiagnosed in India due to subtle childhood features, though detection is improving with expanded prenatal screening.
The Rashtriya Bal Swasthya Karyakram (RBSK) provides free karyotyping and multidisciplinary care under its 4Ds initiative.
ICMR 2024 guidelines mandate offering karyotype testing in boys presenting with tall stature accompanied by hypogonadism or learning disabilities.